Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus PFS in Subjects With Visual Impairment Due to Retinal Disorders, NORSE SEVEN

NCT05112861 is registered in ClinicalTrials.gov with Outlook Therapeutics, Inc. as lead sponsor.

NCT NCT05112861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05112861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus PFS in Subjects With Visual Impairment Due to Retinal Disorders, NORSE SEVEN
Lead sponsor
Outlook Therapeutics, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 15, 2021
Completion date
December 31, 2027
Enrollment
120 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, brvo - branch retinal vein occlusion, diabetic macular edema, neovascular age-related macular degeneration, wet macular degeneration